Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 414-422 , November 2007

Insulin’s actions on plasma free fatty acids are normal in patients with stage 2 to 3 chronic kidney disease

  • Crystal A. Gadegbeku, MD

      Affiliations

    • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
    • Corresponding Author InformationCorresponding author: Crystal A. Gadegbeku, MD, University of Michigan Health System, Department of Medicine, Division of Nephrology, 310 Simpson Memorial Institute, 102 Observatory Road, Ann Arbor, Michigan 48109. Tel: 734-615-3994; fax: 734-615-4887.
    • ,
  • Arachelvi Dhandayuthapani, MD

      Affiliations

    • Internal Medicine and Nephrology, Private Practice, Athens, Georgia, USA
    • ,
  • Timothy P. Taylor, MSRD

      Affiliations

    • Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    • ,
  • Zakarea Shrayyef, MD

      Affiliations

    • Department of Medicine and Physiology, University of Rochester, Rochester, New York, USA
    • ,
  • John Gerich, MD

      Affiliations

    • Department of Medicine and Physiology, University of Rochester, Rochester, New York, USA
    • ,
  • W. Timothy Garvey, MD

      Affiliations

    • Department of Nutrition Sciences, University of Alabama, Tuscaloosa, Alabama, USA
    • ,
  • Brent M. Egan, MD

      Affiliations

    • Department of Medicine and Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA

Received 14 February 2007 ,Accepted 29 May 2007.

References 

  1. Grutzmacher P, Radtke HW, Schifferdecker E, Peschke B, Riepenhausen J, Fassbinder W, et al. Early changes of plasma lipid status and glucose tolerance during the course of chronic renal failure. Contrib Nephrol. 1984;41:332–336
  2. Bergesio F, Monzani G, Ciuti R, Serruto A, Benucci A, Frizzi V, et al. Lipids and apolipoproteins change during the progression of chronic renal failure. Clin Nephrol. 1992;38:264–270
  3. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121–131
  4. Prinsen BH, de Sain–van der Velden MG, de Koning EJ, Koomans HA, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl. 2003;84:S1214
  5. McCosh EJ, Solangi K, Rivers JM, Goodman A. Hypertriglyceridemia in patients with chronic renal insufficiency. Am J Clin Nutr. 1975;28:1036–1043
  6. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson–Ehle P. Evidence that reduced lipoprotein lipase activity is not a primary pathogenetic factor for hypertriglyceridemia in renal failure. Kidney Int. 1995;48:779–784
  7. Kobayashi S, Maesato K, Moriya H, Ohtake T, Ikeda T. Insulin resistance in patients with chronic kidney disease. Am J Kidney Dis. 2005;45:275–280
  8. Coppack SW, Jensen MD, Miles JM. In vivo regulation of lipolysis in humans. J Lipid Res. 1994;35:177–193
  9. Campbell PJ, Carlson MG, Hill JO, Nurjhan N. Regulation of free fatty acid metabolism by insulin in humans: role of lipolysis and re-esterification. Am J Physiol. 1992;263:E1063–E1069
  10. Lewis GF. Fatty acid regulation of very low-density lipoprotein production. Curr Opin Lipidol. 1997;8:146–153
  11. Gadegbeku CA, Dhandayuthapani A, Sadler ZE, Egan BM. Raising lipids acutely reduces baroreflex sensitivity. Am J Hypertens. 2002;15:479–485
  12. Gadegbeku CA, Shrayyef MZ, LaPorte FB, Egan BM. Lipids enhance alpha1–adrenoceptor pressor sensitivity in patients with chronic kidney disease. Am J Kidney Dis. 2004;44:446–454
  13. Stojiljkovic MP, Zhang D, Lopes HF, Lee CG, Goodfriend TL, Egan BM. Hemodynamic effects of lipids in humans. Am J Physiol Regul Integr Comp Physiol. 2001;280:R1674–R1679
  14. Stepniakowski KT, Goodfriend TL, Egan BM. Fatty acids enhance vascular alpha–adrenergic sensitivity. Hypertension. 1995;25:774–778
  15. Haastrup A, Gadegbeku CA, Zhang D, Mukhin YV, Greene EL, Jaffa AA, et al. Lipids stimulate the production of 6–keto–prostaglandin f (1 alpha) in human dorsal hand veins. Hypertension. 2001;38:858–863
  16. Gouveia LM, Moyses–Neto M, Paccola GM, Piccinato CE, Foss MC. Peripheral glucose metabolism in patients with chronic renal failure. Braz J Med Biol Res. 1995;28:201–207
  17. Eidemak I, Feldt–Rasmussen B, Kanstrup IL, Nielsen SL, Schmitz O, Strandgaard S. Insulin resistance and hyperinsulinaemia in mild to moderate progressive chronic renal failure and its association with aerobic work capacity. Diabetologia. 1995;38:565–572
  18. Lee P, O’Neal D, Murphy B, Best J. The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure. Am J Kidney Dis. 1997;29:54–65
  19. Schmitz O, Alberti KG, Christensen NJ, Hasling C, Hjollund E, Beck–Nielsen H, et al. Aspects of glucose homeostasis in uremia as assessed by the hyperinsulinemic euglycemic clamp technique. Metabolism. 1985;34:465–473
  20. Curtin F, Morabia A, Pichard C, Slosman DO. Body mass index compared to dual–energy x–ray absorptiometry: evidence for a spectrum bias. J Clin Epidemiol. 1997;50:837–843
  21. Israelit AH, Long DL, White MG, Hull AR. Measurement of glomerular filtration rate utilizing a single subcutaneous injection of 125I–iothalamate. Kidney Int. 1973;4:346–349
  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low–density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502
  23. Lusk G. Animal calorimetry (Twenty–fourth paper. Analysis of the oxidation of mixtures of carbohydrate and fat). J Biol Chem. 1923;59:41–42
  24. Miles JM, Ellman MG, McClean KL, Jensen MD. Validation of a new method for determination of free fatty acid turnover. Am J Physiol. 1987;252:E431–E438
  25. Meyer C, Nadkarni V, Stumvoll M, Gerich J. Human kidney free fatty acid and glucose uptake: evidence for a renal glucose–fatty acid cycle. Am J Physiol. 1997;273:E650–E654
  26. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32:S142–S156
  27. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int. 2003;63:1121–1129
  28. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003;41:47–55
  29. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: causes and consequences. Curr Opin Nephrol Hypertens. 2002;11:323–329
  30. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia––relation to renal function and dialysis. Nephron. 1991;57:401–410
  31. Attman PO, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int. 1991;(Suppl 31):S1623
  32. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall MJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis. 2001;38:537–546
  33. Lu G, Greene EL, Nagai T, Egan BM. Reactive oxygen species are critical in the oleic acid–mediated mitogenic signaling pathway in vascular smooth muscle cells. Hypertension. 1998;32:1003–1010
  34. Lu G, Morinelli TA, Meier KE, Rosenzweig SA, Egan BM. Oleic acid–induced mitogenic signaling in vascular smooth muscle cells (A role for protein kinase C). Circ Res. 1996;79:611–618
  35. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int. 1992;41:1653–1661
  36. Batista MC, Welty FK, Diffenderfer MR, Sarnak MJ, Schaefer EJ, Lamon–Fava S, et al. Apolipoprotein A–I, B–100, and B–48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome. Metabolism. 2004;53:1255–1261
  37. Prinsen BH, Rabelink TJ, Romijn JA, Bisschop PH, de Barse MM, de Boer J, et al. A broad–based metabolic approach to study VLDL apoB100 metabolism in patients with ESRD and patients treated with peritoneal dialysis. Kidney Int. 2004;65:1064–1075
  38. Egan BM, Hennes MM, Stepniakowski KT, O’Shaughnessy IM, Kissebah AH, et al. Obesity hypertension is related more to insulin’s fatty acid than glucose action. Hypertension. 1996;27:723–728
  39. Hennes MM, O’Shaughnessy IM, Kelly TM, LaBelle P, Egan BM, Kissebah AH. Insulin–resistant lipolysis in abdominally obese hypertensive individuals (Role of the renin–angiotensin system). Hypertension. 1996;28:120–126
  40. Diraison F, Beylot M. Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification. Am J Physiol. 1998;274:E321–E327
  41. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563–568
  42. Fliser D, Pacini G, Engelleiter R, Kautzky–Willer A, Prager R, Franek E, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int. 1998;53:1343–1347
  43. Kato Y, Hayashi M, Ohno Y, Suzawa T, Sasaki T, Saruta T. Mild renal dysfunction is associated with insulin resistance in chronic glomerulonephritis. Clin Nephrol. 2000;54:366–373
  44. Egan BM, Lackland DT, Igho–Pemu P, Hendrix KH, Basile J, Rehman SU, et al. Cardiovascular risk factor control in communities––update from the ASH Carolinas–Georgia Chapter, the Hypertension Initiative, and the Community Physicians’ Network (Greenwich). J Clin Hypertens. 2006;8:879–886
  45. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007;115:450–458
  46. Fagot–Campagna A, Balkau B, Simon D, Warnet JM, Claude JR, Ducimetiere P, et al. High free fatty acid concentration: an independent risk factor for hypertension in the Paris Prospective Study. Int J Epidemiol. 1998;27:808–813

 This work was supported by National Institutes of Health RO1-HL58794 which included a minority supplement, K23 RR15542, K24 HL04290, General Clinical Research Center grants M01 RR01070 (Medical University of South Carolina) and 5 M01 RR 00044 (University of Rochester) from the Division of Research Resources, and research funds from the Paul Teschan Research Fund of Dialysis Clinics, Inc.

PII: S1933-1711(07)00125-8

doi: 10.1016/j.jash.2007.05.004

Journal of the American Society of Hypertension
Volume 1, Issue 6 , Pages 414-422 , November 2007

Article Tools

* Image Usage & Resolution